Etodolac 300mg Tablet Franchise in Ahmedabad

Pain & Inflammation Tablet Supplier in Bangalore

NSAID Tablet Distributor in Hyderabad

Arthritis & Musculoskeletal Pain Tablet Franchise Opportunity in Jaipur

Orthopedic Medicine Tablet Stockist in Mumbai
Etodolac Tablet Export & Manufacturing in Chandigarh

Home/Products /etodolac-300mg-tablet

Edofoam ER 300 Tablet

Composition : Etodolac (300mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

Edofoam ER 300 Tablet contains Etodolac 300mg, an extended-release NSAID designed for the management of pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and musculoskeletal disorders. Its formulation provides sustained relief over a prolonged period, reducing the need for frequent dosing.

The 300mg strength ensures effective analgesia and anti-inflammatory action while maintaining a favorable tolerability profile. It is ideal for patients requiring consistent pain control and improved mobility.

For hospitals, orthopedic clinics, and distributors, Edofoam ER 300 Tablet is a high-demand pain management product, widely prescribed in orthopedic departments, physiotherapy centers, and multispecialty hospitals. Regular use ensures steady orders and strong market presence.

Adding Edofoam ER 300 Tablet to your portfolio strengthens your pain management and orthopedic segment, creating opportunities in hospital procurement, pharmacy distribution, institutional orders, export markets, and third-party manufacturing. Its clinical reliability and patient-friendly extended-release profile make it a valuable addition for pharmaceutical distributors.+++

Read More

About the Product

Edofoam ER 300 Tablet contains Etodolac 300mg, an extended-release NSAID designed for the management of pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and musculoskeletal disorders. Its formulation provides sustained relief over a prolonged period, reducing the need for frequent dosing.

The 300mg strength ensures effective analgesia and anti-inflammatory action while maintaining a favorable tolerability profile. It is ideal for patients requiring consistent pain control and improved mobility.

For hospitals, orthopedic clinics, and distributors, Edofoam ER 300 Tablet is a high-demand pain management product, widely prescribed in orthopedic departments, physiotherapy centers, and multispecialty hospitals. Regular use ensures steady orders and strong market presence.

Adding Edofoam ER 300 Tablet to your portfolio strengthens your pain management and orthopedic segment, creating opportunities in hospital procurement, pharmacy distribution, institutional orders, export markets, and third-party manufacturing. Its clinical reliability and patient-friendly extended-release profile make it a valuable addition for pharmaceutical distributors.+++

Common side effects include nausea, indigestion, dizziness, or mild gastrointestinal discomfort. Rarely, it may cause allergic reactions or gastrointestinal bleeding.

Used to relieve pain and inflammation associated with arthritis and other musculoskeletal conditions.

Avoid use if you have a known allergy to NSAIDs. Consult your doctor if you experience severe side effects or signs of gastrointestinal bleeding.

Store in a cool, dry place at room temperature, away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation